Do Wall Street Analysts Like Insulet Stock?
/Insulet%20Corporation%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Acton, Massachusetts-based Insulet Corporation (PODD) is a medical device company that develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. With a market cap of $22.8 billion, Insulet’s operations span the United States, Canada, Europe, the Middle East, Australia, and internationally.
Shares of PODD have significantly outpaced the broader market over the past 52 weeks. PODD stock has soared 77.3% over this period, while the broader S&P 500 Index ($SPX) has gained 10.1%. Moreover, shares of PODD are up 23% on a YTD basis, compared to SPX’s marginal dip.
Zooming in further, Insulet has also outperformed the iShares U.S. Medical Devices ETF’s (IHI) 7.6% rise over the past year and 4.3% return in 2025.
Insulet’s stock prices surged 20.9% in the trading session after the release of its strong Q1 2025 results on May 8. The company reported revenue of $569 million, up 28.8% from the prior-year quarter, driven by robust growth in the U.S. and expanding international demand. The figure also exceeded Street expectations of $542.1 million. Adjusted EPS came in at $1.02, beating analysts’ estimates by 25.9%.
Looking ahead to fiscal 2025, Insulet raised its guidance, boosting investor confidence. The company now expects total Omnipod sales to grow between 20% and 23%, up from the previous range of 17% to 21%. Total revenue growth is projected to be between 19% and 22%, compared to earlier guidance of 16% to 20%.
For the current fiscal year 2025, ending in December, analysts expect PODD's adjusted EPS to increase 33% year-over-year to $4.31. The company has a mixed earnings surprise history. It beat the Street's bottom-line estimates in three of the past four quarters while missing on one occasion.
Among the 22 analysts covering PODD stock, the consensus rating is a “Strong Buy.” That’s based on 17 “Strong Buy” ratings, two “Moderate Buys,” and three “Holds.”
On May 22, Citigroup (C) analyst Joanne Wuensch reiterated a “Buy” rating on PODD and raised the price target to $380, suggesting an 18.4% upside potential from current price levels.
As of writing, Insulet’s mean price target of $328.76 implies a modest 2.4% premium to current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.